ABSTRACT
Objective To study the clinical efficacy of nimotuzumab combined with concurrent chemoradio therapy in the treatment of locally advanced esophageal carcinoma . Methods 80 patients with locally advanced esophageal carcinoma were selected as subjects. They were divided into the control group and the treatment group according to the random number table method, with 40 cases in each group. The control group was treated with docetaxel plus cisplatin(TP) chemotherapy combined with radiotherapy,and the treatment group was treated with nimotuzumab combined with concurrent chemoradiotherapy. 21 days for a period of treatment and the two groups were treated for 3 periods. The clinical efficacy of the two groups after treatment was evaluated and compared. The serum carbohydrate antigen 125 ( CA125 ) , carbohydrate antigen 199 ( CA199 ) , carbohydrate antigen 724 ( CA724 ) , carcinoembryonic antigen( CEA) and squamous cell carcinoma antigen( SCC) levels of the two groups before and after treatment were calculated and compared. The incidence rate of adverse reactions, including radioactive esophagitis, radioactive pneumonia,hematology toxicity and allergic reaction were calculated and compared between the two groups during the treatment. Results The effective rate of the treatment group was 80. 00%,which was significantly higher than 57. 50% of the control group(χ2 =4. 713,P=0. 030). The serum CA125,CA199,CA724,CEA and SCC levels of the treatment group after treatment were (30. 18 ± 4. 14) U/mL,(32. 42 ± 3. 67) U/mL,(7. 48 ± 1. 12) U/mL, (11. 68 ± 2. 02 )μg/L, ( 0. 73 ± 0. 17 ) ng/mL, which were significantly lower than those of the control group [(44.27 ±6. 42) U/mL,(53. 93 ± 5. 17) U/mL,(15. 03 ± 2. 54) U/mL,(25. 22 ± 3. 27)μg/L,(1. 61 ± 0. 28)ng/mL](t=11. 665,21. 457,17. 201,22. 280,16. 991,all P<0. 05). There were no significant differences in the incidence rates of adverse reactions, including the radioactive esophagitis, radioactive pneumonia, hematology toxicity and allergic reaction (7. 50% vs. 10. 00%,10. 00% vs. 12. 50%,2. 50% vs. 5. 00%,12. 50% vs. 15. 00%) between the two groups(χ2 =0. 157,0. 125,0. 346,0. 105,all P>0. 05). Conclusion Nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced esophageal carcinoma has remarkable clinical efficacy and good safety,which can significantly reduce the serum CA125,CA199,CA724,CEA and SCC levels,and it is worthy of clinical application.
ABSTRACT
Objective To study the clinical efficacy of nimotuzumab combined with concurrent chemoradio therapy in the treatment of locally advanced esophageal carcinoma . Methods 80 patients with locally advanced esophageal carcinoma were selected as subjects. They were divided into the control group and the treatment group according to the random number table method, with 40 cases in each group. The control group was treated with docetaxel plus cisplatin(TP) chemotherapy combined with radiotherapy,and the treatment group was treated with nimotuzumab combined with concurrent chemoradiotherapy. 21 days for a period of treatment and the two groups were treated for 3 periods. The clinical efficacy of the two groups after treatment was evaluated and compared. The serum carbohydrate antigen 125 ( CA125 ) , carbohydrate antigen 199 ( CA199 ) , carbohydrate antigen 724 ( CA724 ) , carcinoembryonic antigen( CEA) and squamous cell carcinoma antigen( SCC) levels of the two groups before and after treatment were calculated and compared. The incidence rate of adverse reactions, including radioactive esophagitis, radioactive pneumonia,hematology toxicity and allergic reaction were calculated and compared between the two groups during the treatment. Results The effective rate of the treatment group was 80. 00%,which was significantly higher than 57. 50% of the control group(χ2 =4. 713,P=0. 030). The serum CA125,CA199,CA724,CEA and SCC levels of the treatment group after treatment were (30. 18 ± 4. 14) U/mL,(32. 42 ± 3. 67) U/mL,(7. 48 ± 1. 12) U/mL, (11. 68 ± 2. 02 )μg/L, ( 0. 73 ± 0. 17 ) ng/mL, which were significantly lower than those of the control group [(44.27 ±6. 42) U/mL,(53. 93 ± 5. 17) U/mL,(15. 03 ± 2. 54) U/mL,(25. 22 ± 3. 27)μg/L,(1. 61 ± 0. 28)ng/mL](t=11. 665,21. 457,17. 201,22. 280,16. 991,all P<0. 05). There were no significant differences in the incidence rates of adverse reactions, including the radioactive esophagitis, radioactive pneumonia, hematology toxicity and allergic reaction (7. 50% vs. 10. 00%,10. 00% vs. 12. 50%,2. 50% vs. 5. 00%,12. 50% vs. 15. 00%) between the two groups(χ2 =0. 157,0. 125,0. 346,0. 105,all P>0. 05). Conclusion Nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced esophageal carcinoma has remarkable clinical efficacy and good safety,which can significantly reduce the serum CA125,CA199,CA724,CEA and SCC levels,and it is worthy of clinical application.